Pancreatic Cancer | Specialty

Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer

November 17th 2024

Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.

Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.

The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.

DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.

Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.

RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer

October 28th 2024

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.

Dr Bekaii-Saab on Frontline Treatment Considerations for BRCA1/2+ Pancreatic Cancer

October 25th 2024

Tanios Bekaii-Saab, MD, FACP, discusses the evolving treatment paradigm for BRCA1- and BRCA2-positive pancreatic cancer in the first-line setting.

FDA Grants Orphan Drug Designation to IMM-1-104 for Pancreatic Cancer

October 15th 2024

The FDA has granted orphan drug designation to IMM-1-104 for pancreatic cancer.

Dendritic Cell–Based Immunotherapy Data in Resected Pancreatic Cancer Published in JCO

September 27th 2024

MesoPher cell therapy led to a 2-year recurrence-free survival rate of 64% and low-grade AEs in resected pancreatic cancer following chemotherapy.

LODER Plus SOC Chemotherapy Elicits Responses, Boosts OS in KRAS+ Unresectable, Locally Advanced Pancreatic Cancer

September 24th 2024

LODER plus chemotherapy led to responses and improved overall survival in unresectable, locally advanced pancreatic cancer.

Narmafotinib Earns FDA Fast Track Designation for Advanced Pancreatic Cancer

September 20th 2024

The FDA has granted fast track designation to narmafotinib for the treatment of advanced pancreatic cancer.

IMM-1-104 and Chemo Combination Elicit Responses in First-Line Pancreatic Cancer

September 13th 2024

First-line IMM-1-104 combined with modified gemcitabine/nab-paclitaxel elicited both partial and complete responses in patients with pancreatic cancer.

Awareness Efforts Needed to Address Genetic Testing Disparities Among Male BRCA1/2 Carriers

August 20th 2024

Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.

Hood on the Association Between BRCA Mutations and Primary Tumor Location in PDAC

August 19th 2024

Ryan Hood, BA, discusses a study investigating the association between BRCA1/2 pathogenic variants and primary tumor location in pancreatic cancer.

Dr Goodman on the Addition of CRT to Adjuvant Chemo in Pancreatic Head Adenocarcinomas

August 12th 2024

Karyn A. Goodman, MD, MS, discusses the use of chemoradiation after adjuvant chemotherapy in resected adenocarcinomas of the pancreatic head.

Dr Maxwell on Cancer Risk for Males Carrying Germline BRCA Mutations

August 9th 2024

Kara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.

IMM-1-104 Earns FDA Fast Track Designation for First-Line PDAC

August 1st 2024

The FDA granted fast track designation to IMM-1-104 for first-line pancreatic ductal adenocarcinoma.

Pamrevlumab Fails to Provide OS Benefit in Pancreatic Cancer

July 31st 2024

Two late-stage trials investigating the efficacy and safety of pamrevlumab in pancreatic cancer failed to meet their primary end points of OS.

RAS-Directed Therapy and Patient Selection Are Sectors to Watch in Pancreatic Cancer

July 24th 2024

Eileen M. O'Reilly, MD, details how RAS-directed therapy could potentially change the pancreatic cancer landscape and highlights updated data in the space.